annb0t
Top 20
Immutep Limited
Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) Planning and regulatory interactions ongoing with a focus now prioritising 1st line (1L) NSCLC New and important clinical data in 1L NSCLC expected in Q4 2022 Continued expansion of efti in additional indications and combinations planned Strong balance sheet provides cash runway into...
>>> Read more: Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) Planning and regulatory interactions ongoing with a focus now prioritising 1st line (1L) NSCLC New and important clinical data in 1L NSCLC expected in Q4 2022 Continued expansion of efti in additional indications and combinations planned Strong balance sheet provides cash runway into...
>>> Read more: Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
